Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus Inc. (NASDAQ: AGEN) announced its inaugural Agenus Insights webinar titled “Optimally Targeting TIGIT” on February 11, 2021, at 1:00 p.m. ET. The event will feature a 15-minute presentation followed by a Q&A session led by Dr. Steven O’Day and Dr. Dhan Chand. The focus will be on the clinical validation of TIGIT as a cancer target and Agenus' innovative design. Registration is available online, and a replay will be accessible post-event on the company’s website.
Agenus Inc. (NASDAQ: AGEN) reported promising results from its Phase 1/2 trial of AGEN1181, a next-generation anti-CTLA-4 antibody. The trial confirmed six objective clinical responses in patients with colon, ovarian, and endometrial cancers, showcasing AGEN1181's efficacy, particularly in difficult-to-treat tumors. No significant toxicities were observed, marking a notable improvement over existing therapies like ipilimumab. Phase 2 trials in additional cancer indications are set to begin soon, highlighting the company's commitment to advancing cancer immunotherapy.
Agenus Inc. (NASDAQ: AGEN) reported positive preliminary results from its Phase 1 trial of iNKT cell therapy aimed at patients with moderate to severe COVID-19 symptoms. Conducted by AgenTus Therapeutics, the trial showcased that 3 out of 4 intubated patients were discharged after treatment, and 2 patients were extubated within 24 hours of dosing. The company is currently in the dose escalation phase, with plans to initiate a Phase 2 trial by mid-2021, and data readouts expected by Q4 2021. Early results indicate good tolerance and potential benefits of the therapy for severely ill patients.
Agenus Inc. (NASDAQ: AGEN) has announced a clinical collaboration with Nelum Corp. to evaluate the combination of zalifrelimab, its anti-CTLA-4 antibody, and Nelum's NLM-001 with chemotherapy for first-line advanced pancreatic cancer. The trial aims to assess the safety and efficacy of this combination. Under the agreement, Agenus will supply zalifrelimab, while Nelum will sponsor and conduct the trial, expected to begin enrolling in the first half of 2021. This collaboration is seen as a strategic move to enhance the therapeutic potential of Agenus' pipeline.
Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, and Dr. Steven O’Day, CMO, will participate in the B. Riley Securities’ Oncology Investor Conference on January 20-21, 2021. The conference will feature a fireside chat with Dr. Buell on January 21 from 10:30 am to 11:00 am, accessible via a live webcast. Additionally, both doctors will engage in a panel discussion on novel immunotherapies. Recorded replays will be available on Agenus' Events & Presentations page post-conference.
Agenus Inc. (NASDAQ: AGEN) announced an updated timeline for the Biologics License Application (BLA) filing of balstilimab, necessitated by FDA feedback for a 12-month follow-up on all trial patients and a 6-month follow-up on responders. Two late responses in the clinical trial prompted this strategy adjustment, with the BLA filing now expected in the first half of 2021. The company is also clarifying PD-L1 diagnostic requirements with the FDA. This follow-up will provide data on patients achieving durable disease stabilization through long-term therapy.
Agenus Inc. (NASDAQ: AGEN) has expanded its Phase 2 trial for AGEN1181 in colorectal cancer following a promising clinical response. A significant tumor reduction of 27% was observed in a patient, alongside disease stabilization in 19 out of 41 treated patients. The trial also reported four clinical responses and the potential to treat tumors traditionally unresponsive to immune therapies. The company aims to broaden the patient population benefiting from cancer immunotherapies through innovative combination approaches.
Agenus Inc. (NASDAQ: AGEN) announced Dr. Jennifer Buell, President and COO, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, from 10:55 AM to 11:15 AM EST. Dr. Buell is set to provide updates on clinical programs, specifically AGEN1181, and the company's overall progress. Interested individuals can register for the webinar in advance. A replay will be available post-event on the Agenus website's Events & Presentations page.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology firm, announced Dr. Jennifer Buell's participation in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, from 4:25 PM - 4:55 PM GMT. This event will highlight the company’s innovative pipeline of immune therapies, including checkpoint antibodies and vaccines aimed at enhancing immune responses against cancer. Interested parties can register for the webinar and access a replay on the Agenus website.
Agenus Inc. (NASDAQ: AGEN) announced a webcast on November 16, 2020, featuring Dr. Steven O’Day and other key figures discussing AGEN1181 and its Ph1 trial results. Dr. O’Day will review initial responses in patients with microsatellite stable disease and implications of Treg depletion. Dr. Jennifer Buell and Dr. Dhan Chand will outline next steps for AGEN1181 and share insights on its other drug programs, including AGEN2373 and AgenT-797. Registration is available online, and a replay will be accessible on the Agenus website post-event.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?